Tailoring Treatment Approaches in Psoriasis Management - Episode 11
Examining the Relationship Between Psoriasis and Psoriatic Arthritis
Panelists discuss how the SPECTREM trial (Glick, 2024) revealed guselkumab’s exceptional site-specific efficacy for psoriasis in traditionally difficult-to-treat areas, achieving complete clearance (Investigator’s Global Assessment [IGA] 0) in remarkably high proportions of patients compared with placebo—with 60% clearance in scalp (vs 9% for placebo), 76% in facial sites (vs 24%), 77% in intertriginous areas (vs 24%), and 73% in genital regions (vs 33%)—while maintaining a favorable safety profile without new signals, demonstrating the biologic’s particular value for patients with limited but high-impact disease in these psychologically and functionally significant locations.
Video content above is prompted by the following:
a. A high proportion of patients were able to achieve complete skin clearance (IGA 0) across all special sites at week 16 (Glick, 2024).
i. Scalp 60% vs placebo 9%
ii. Face 76% vs placebo 24%
iii. Intertriginous 77% vs placebo 24%
iv. Genital 73% vs placebo 33%
b. No new safety signals identified.
